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Abstract In the pharmaceutical industry, systems for
improving operational effectiveness and efficiency are
becoming more and more popular. In this paper, develop-
ments in the industry’s improvements in operational
effectiveness and efficiency have been analyzed. A holistic
model is presented which builds the basis for the presented
study results. The study includes data gathered from
pharmaceutical production sites in surveys in 2004 and
2009. The analysis is divided according to the four sub-
systems: Total Productive Maintenance, Total Quality
Management, Just-in-Time, and the Management System.
For each sub-system, key performance indicators and
associated elements (practices and instruments) from 2004
to 2009 are investigated. The data indicates that the
industry did make continuous steps towards “Excellence
in Operations” between 2004 and 2009. Pharmaceutical
companies took control over their former low asset
utilization and managed to improve the efficiency of their
quality systems; however, they are still far away from
having any kind of “continuous flow”, smooth production
scheduling or make-to-order manufacturing. It can be said
that most of the companies are still working on the
effectiveness side rather than focusing on the efficiency
side.
Keywords Pharmaceutical manufacturing . Operational
excellence . Total quality management . Just-in-time .
Effective management system . Total productive
maintenance . Lean production
Background
The pharmaceutical industry is facing severe quality
problems. The Food and Drug Administration (FDA) is
reporting an increase by 309% from 426 drug recalls in
2008 to 1,742 drug recalls in 2009 [1]. Some of the recalls
may be triggered by an increase of FDA inspections of
production facilities. But, the large majority of the issues
leading to the recalls of drugs on the global market can be
traced back to shortcomings in supply and manufacturing
such as poor quality of raw materials, incorrect packaging,
and contamination of products. The incident with heparin
that resulted in 484 deaths in 2007 and 2008, was the
outcome of deviations from “current good manufacturing
practices” (cGMP) in the production and quality control of
the drug’s active pharmaceutical ingredient, manufactured
by Chinese suppliers [2, 3]. Additionally, examples of
issues with production sites of established pharmaceutical
companies in the USA and Western Europe lead to the
conclusion that poor quality is not only an issue for low-
cost production countries. The cGMP and contamination
issues with the Genzyme facility in Allston Landing, one
of the largest cell-culture manufacturing plants in June
2009 resulted in an expenditure of $184.2 million for
decontamination and fine and an estimated loss in
revenue of $1 billion [4].
Due to the recent incidents, pharmaceutical companies
either with in-house manufacturing or with external
contract manufacturing are concerned with the capability
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of their processes to manufacture the drug according to
specifications while keeping manufacturing costs within
reasonable limits [5]. Although only few senior executives
see manufacturing as a competitive advantage, it is
understood that lacking high quality management and
capability of pharmaceutical manufacturing can lead to
disasters. Therefore, companies are forced to implement
approaches such as lean manufacturing which has proven to
be capable of improving effectiveness and efficiency of
production in a number of industries [6]. The term
“Operational Excellence” (OPEX) as a target state for lean
manufacturing is used by the pharmaceutical industry to
describe their efforts in improving effectiveness and
efficiency in operations [7].
Objectives
The main objective of this study was to assess and analyze
the implementation levels of “Operational Excellence”
across the pharmaceutical industry. For this analysis, a
research model is used showing an integrated “Operational
Excellence” model. It includes the major principles of Total
Productive Maintenance, Total Quality Management, and
Just-in-Time as well as the “social principle” of the
Effective Management System. The information from
pharmaceutical companies gathered in surveys in 2004
and 2009 was used in the analysis. The main objective can
be divided into the following sub-objectives:
– Gain a better understanding of the actual implementa-
tion of Total Productive Maintenance, Total Quality
Management, Just-in-Time, and Effective Management
System in the industry.
– Study the link between the implementation of the
named systems and key performance indicators
(KPIs).
– Explore the trend of KPIs and implementation levels
between 2004 and 2009 in the industry.
Methodology
The data used in this work were extracted from surveys
conducted in 2004 to 2009 by the University of St. Gallen,
Switzerland. The participating companies were brand-
name, generics, and contract manufacturer companies both
from the pharmaceutical and the biologic businesses. The
research sample includes companies ranging from small- to
medium-sized to large corporations (Fig. 1). The survey
was completed by the representatives of the companies’
production sites; therefore, the data received include figures
for the entire production site.
Research Model
The survey’s questionnaire is derived from a model which
was developed in 2004 [7]. The original non-industry-
specific model [8] has been detailed in close cooperation
with pharmaceutical companies to meet the requirements of
pharmaceutical production. The research model is shown in
Fig. 2.
In the model, a distinction is made between four sub-
systems in OPEX: Total Productive Maintenance (TPM),
Total Quality Management (TQM), Just-in-Time (JIT), and
the Effective Management System (EMS). Each sub-system
represents in itself an important part which contributes to
the overall success. In fact, the included elements reinforce
each other. According to this model, manufacturing is
viewed as a system in which single elements or interven-
tions have a direct and indirect impact on other sub-systems
and elements.
TPM represents a system for the effective usage of process
technology. TPM is designed to efficiently manage fixed
assets such as machines, equipment, and property throughout
their life cycle [9] and includes the following elements:
– Preventive maintenance
– Housekeeping
– Effective technology usage
It does not only focus on the technical aspects such as
the reliability of existing equipment and a careful selection
of new technologies, but also the engagement of all
employees in the production environment, from manage-
ment level to shop-floor employees in maintenance-related
activities [10]. In OPEX programs, TPM is the basis for
stable running machines and therefore forms the basis for
further in-depth improvements in efficiency [7].
TQM describes a quality culture in companies that
addresses all direct and indirect employees, rather than
solely employees in Quality Control (QC) and Quality
Assurance (QA) departments [11]. Consequently, TQM
does not only affect manufacturing but several additional
functions, e.g., research and development (R&D) and
supplier management. It means people management, com-
mitment from top to down, and strive for continuous
improvement across the entire organization. Sustainably
improving the quality of products, processes, and overall
company quality is the objective of TQM. The following
elements are part of TQM:
– Process management
– Cross-functional product development
– Customer involvement
– Supplier quality management
JIT aims at continuously reducing all types of waste,
especially by reducing inventory and unnecessary delays in
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production flow [11, 12]. JIT manufacturing has become a
crucial element for most companies in the last years to
increase flexibility without building up huge inventories.
The elements of JIT in the OPEX model are:
– Set-up time reduction
– Planning adherence
– Pull system
– Layout optimization
The EMS is an essential requirement for achieving
OPEX. Plant managers should provide the right framework
for OPEX. Various actions by managers are contributing to
the efficiency of operations [8]. The ultimate task of plant
management is leveraging employee potential by clear
direction setting, dedicated management commitment, and
functional integration. Four elements of EMS were inves-
tigated:
– Direction setting
– Management commitment and company culture
– Employee involvement and continuous improvement
– Functional integration and qualification
Data Analysis
For each of the elements, several statements were listed in
the survey to be completed on a five-point Likert scale [13,
14] by the participating pharmaceutical sites. For assessing
the performance, the definitions for the key performance
indicators were given in the survey (see Appendix).
To compare the data in the four sub-systems across the
pharmaceutical companies in this survey, the median scores
of the extracted data were calculated for the implementation
levels and the key performance indicators. These median
scores were used for the analysis.
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Assumptions and Limitations
The authors are dependent on the data reported by the
representatives of the pharmaceutical sites. It is possible
that representatives answered more positively in order to
achieve better results in the survey. As the survey was
completed by representatives on management level, it could
be the case that answers by them do not reflect the overall
opinion of the employees of different hierarchical levels at
the production site. For example, the elements of the
sub-system EMS could be assessed more positively
because it is completed by a manager as this does not
represent the overall opinion of the workers.
The analysis includes pharmaceutical and biotechnological
production sites. Although both types of production processes
include different sub-processes, e.g., biotechnological pro-
duction includes purification; it is assumed that the core
procedure to produce a drug is comparable: (1) API
production, (2) Formulation, and (3) Packaging. The analysis
is limited to this “process level” and does not consider the
differences between single process steps in pharmaceutical
and biotechnological production.
Key Observations
Total Productive Maintenance
The trend of the KPIs “Overall equipment effectiveness”
and “Unplanned maintenance” as well as of the implemen-
tation of techniques of preventive maintenance, technology
usage, and housekeeping is analyzed. The figures for 2004
and 2009 are illustrated in Fig. 3.
An increase in overall equipment effectiveness (OEE) of
15% from 36% in 2004 to 51% in 2009 could be observed.
However, even then, an OEE of 51% (median) measured in
2009 is not really outstanding when compared with other
process industries and their packaging processes. Various
cross-industry studies show an OEE of 60% for an average
production site in the food and beverages sector [15, 16].
This means that pharmaceutical companies still have potential
with regard to higher utilization in scheduled time, prevention
of downtimes, and avoidance of quality losses.
In fact, the non-availability of equipment and
machines as a result of direct stoppages and breakdowns
seems to be a problem for the industry. In 2004, the
proportion of unplanned maintenance work as a percent-
age of the overall time spent for maintenance work
amounted to 25%. Five years later, the figure for
unplanned maintenance increased by 8% to 33%. It can
be argued that this may be one of the reasons why most
pharmaceutical companies struggle with the establish-
ment of stable running manufacturing processes.
Companies were able to slightly increase their level of
“Preventive maintenance” from 2004 (industry median of
71%) to 2009 (75%). In practice, companies have installed
formal programs on operational levels for maintaining their
equipment and machines. Nonetheless, pharmaceutical
companies still reveal shortcomings in TPM which they
have not addressed during these years. Practices especially
pointing to autonomous maintenance by empowering shop-
floor employees are not very common. Maintenance tasks
are still performed mainly by maintenance specialists rather
than by machine operators. In summary, maintenance
systems and processes in the pharmaceutical companies
are still reactive rather than proactive such as planning
maintenance programs based on failure analyses.
The 2004 analysis revealed that the pharmaceutical
industry is very restrictive when it comes to the implemen-
tation of new production technologies. This might be
caused by the fact that every change in the production
process, including the usage of new technologies, needed to
be approved by the regulatory authorities. The element
“Technology Usage” points to the screening of the market
2009 75 %
2004 71 % +6%
Implementation levels
Preventive maintenance
2009 51 %
2004 36 %
+42%
Key performance indicators
Overall equipment ef fectiveness (OEE)
2009 33 %
2004 25 %
+32%
Unplanned maintenance
2009 58 %
2004 57 % +2%
Technology usage
2009 80 %
2004 80 % 0%
Housekeeping
Mean Standard Deviation
43% 18%
48% 20%
Mean Standard Deviation
31% 20%
30% 18%
Mean Standard Deviation
72% 15%
75% 11%
Mean Standard Deviation
56% 16%
58% 14%
Mean Standard Deviation
77% 16%
77% 15%
Fig. 3 Total productive maintenance: key performance indicators and implementation levels
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for new production technologies and the assessment of
technical and financial benefit. Moreover, it includes the
effective use of new technologies. With 58% in 2009
compared with 57% in 2004, this element has not
undergone any essential change. The authors believe that
this can only change with extensive implementation of
Quality by Design where pharmaceutical companies will be
pre-approved by the regulatory agencies to implement
process changes within a specified range of critical process
parameters also known as the “Design Space”.
A high score of 80% in 2004 could be re-observed in
2009 for the element “Housekeeping”. Pharmaceutical
companies seem to do this well as good “Housekeeping”
is seen as the first step getting regulatory approvals. The
vast majority of pharmaceutical companies have beholden
their employees to keep their plant “neat and clean” and
provide tools such as housekeeping checklists.
Total Quality Management
A comparison between the performance indicators, assess-
ing upstream quality (complaint rate supplier), internal
process quality (rejected batches) and for downstream
quality (complaint rate customer), in 2004 and 2009 is
done. Furthermore, the implementation levels of factors
such as “Process management”, “Cross-functional product
development”, “Customer involvement”, and “Supplier
quality management” are investigated (Fig. 4).
Only six out of 1,000 customer orders delivered resulted
in a complaint by the customer in 2009, compared with ten
out of 1,000 in 2004. Rejected batches as a percentage of
all batches produced, a core measure of the process quality,
decreased from 1.00% in 2004 to 0.74% in 2009. More
transparent scale-up processes and teamwork of R&D,
manufacturing, and QC/QA departments mainly caused this
result.
Despite the fact that companies tried to build up stronger
relationships with their suppliers, they were not able to
reduce the upstream complaint rate. Supplier complaint rate
increased from 1.0% in 2004 to 2.4% in 2009. One
explanation is the increase of requirements concerning the
quality of supplies on the manufacturers’ side. Another,
more alarming interpretation, is the decrease in supplier
quality due to increased outsourcing and increase in
complexity of supply chains. It would be worthwhile to
keep a close eye on this factor as outsourcing seems to be
on rise and the complexities of managing quality of global
supply chains is putting increased pressure on pharmaceu-
tical companies’ quality departments.
The implementation element “Process Management”
includes the documentation, measurement, and improve-
ment of processes. Comparing the results from 2004 to
2009, a slight decrease from 70% to 68% in “Process
Management” implementation can be seen among the
participating companies. Documentation and standardiza-
tion based on cGMP in pharmaceutical manufacturing is
established since decades and, consequently, very high
scores regarding these practices are found. Of greater
concern is the fact that measurement methods using
statistical process control or process analytical technology
and assessment using root-cause analyses (e.g., DMAIC
cycle) are implemented only in some very advanced brand-
name companies’ manufacturing sites.
A remarkable development from 2004 to 2009 could be
observed in the implementation of “Cross-functional prod-
uct development”. Its value increased from 30% to 68%
Implementation levelsKey performance indicators
Complaint rate (customer)
Rejected batches
Complaint rate (supplier)
2009 0.55 %
2004 1.00 %
-45%
2009 0.74 %
2004 1.00 %
-26%
2.4 %
2004
2009
1.0 % +140%
Cross-functional product development
Customer involvement
Supplier quality management
Process management
30 %2004
2009 68 %
+127%
73 %
2004
2009
48 % +52%
66 %
2004
2009
60 % +10%
2004
68 %2009
70 % -3%
Mean Standard Deviation
2.5% 4.2%
1.6% 2.3%
Mean Standard Deviation
3.5% 14.7%
1.1% 1.2%
Mean Standard Deviation
68% 18%
65% 13%
Mean Standard Deviation
62% 20%
67% 19%
Mean Standard Deviation
72% 16%
71% 14%
Mean Standard Deviation
1.6% 1.9%
3.5% 4.7%
Mean Standard Deviation
61% 14%
67% 9%
Fig. 4 Total quality management: key performance indicators and implementation levels
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during these 5 years. Generally, “Cross-functional product
development” aims at the translation of customer require-
ments (external and internal customers) into high quality
products. With focus on the manufacturing environment, it
means the close link between development (product and
process) and manufacturing. The increase in this category
shows that pharmaceutical companies are concerned with
the separation of development and manufacturing and has
made significant improvements. By 2009, companies
established a closer collaboration between the R&D and
manufacturing departments with the ultimate objective to
shorten the time for scale-ups by moving from “quality by
inspection” to “quality by design”. In 2009, manufacturing
engineers are more involved in the development of products
and necessary production processes. It could also be a
reflection of headcount reduction in pharmaceutical R&D’s
necessitating engineers in development and manufacturing
to assume multiple roles.
Another improvement reveals the widespread under-
standing that it is essential to know what customers want in
order to stay competitive by providing products that meet
their requirements. Pharmaceutical companies were able to
increase their implementation level in the category of
“Customer Involvement” from 48% in 2004 to 73% in
2009. Customers now frequently give feedback on quality
and delivery performance to pharmaceutical manufacturers
leading to continuous improvement. Nonetheless, there is
still room for improvement regarding the assessment of
customer requirements and proactive management of key
customers.
Starting with a higher median value of 60% in the
category “Supplier Quality Management” compared with
“Customer Involvement”, an increase to 66% could be
observed. The category addresses the integration of
suppliers into the internal quality system to ensure high
quality levels. The vast majority of the companies mark
quality as their number one criterion in selecting suppliers
and not solely the product price. Furthermore, validation
and qualification of suppliers play critical roles for
pharmaceutical manufacturers. Yet, companies hesitate to
deploy joint improvement programs with suppliers to
increase overall process quality.
Just-In-Time
JIT performance indicators pointing to time-to-customer
and working capital are compared in Fig. 5. The level of
JIT implementation is analyzed by observation of four
critical elements: “Set-up time reduction”, “Pull produc-
tion”, “Layout optimization”, and “Planning adherence”
(Fig. 5).
Times required for production process steps deteriorated
between 2004 and 2009. Set-up times deteriorated from
79 min in 2004 to 93 min in 2009. This seems to be
surprising due to the fact that pharmaceutical companies are
looking for learnings in other industries, e.g., modules
which can be maintained and set up without stopping the
entire production process. However, as these approaches
mainly focus on the packaging process, companies were not
able to share such approaches across formulation and
packaging leading to the industry’s shortcoming in set-up
time reductions [17]. Similar to that, the trend for cycle
times shows that pharmaceutical companies are struggling
with process optimization and synchronization which leads
to a negative impact on set up and cycle time. Time from
weighting to packaging (cycle time) did increase from
22.0 days in 2004 to 22.7 days in 2009.
On the other hand, metrics concerning the management
of working capital could be improved. Companies were
able to increase raw material turns from four in 2004 to five
in 2009. It can be argued that companies were able to link
their production to suppliers with the objective of creating a
“pull” instead of the traditional “push” system [18]. In
addition, finished goods turns increased from nine in 2004
to 12 in 2009. After decades of building up huge
inventories, companies are now concerned with having
immense stocks of final products. A re-thinking towards
“producing only what the customer demands” contributed
to the improvement in finished goods turns. With 95%
order fulfillment on time, in the right quantity and right
quality, this figure stayed stable from 2004 to 2009.
With regard to practices and factors linked with “Set-up
time reduction”, companies were able to increase it slightly
from 52% in 2004 to 60% in 2009. Particularly, advance-
ments are seen in the planning of set up and cleaning. In
fact, companies managed to schedule a majority of their
setups so that the regular uptime of machines and
equipment is not affected. The corresponding documenta-
tion and sharing of successful set up and cleaning
procedures are other aspects which were improved across
the pharmaceutical industry.
The low median score for the element “Pull production”
of 44% in 2004 could be increased to 59% in 2009.
Pharmaceutical companies built the basis for a pull system
of the supply chain, e.g., with long-term relationships with
suppliers. However, operational approaches such as a pull
system for internal production processes (including Kanban
containers and signals) and the demand-driven refill of
supplies are still not very common in pharmaceutical
production.
For the two elements “Layout optimization” and “Plan-
ning adherence”, alarming results could be revealed.
Clearly, layout optimization has been neglected because
its value of 68% in 2004 decreased to 57% in 2009. While
“technical” parts of the production layout are optimized,
elements impacting flow and takt (takt is used to match the
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pace of work to the average pace of customer demand)
within production show a very low degree of implementa-
tion. Processes and machines are located close together
with the objective to minimize material handling and
storage of parts. However, manufacturing processes are
not synchronized or managed by the customer’s takt.
Additionally, the core process from raw material to finished
goods still involves a number of interruptions and can
therefore not be described as a full continuous flow.
Another shortcoming can be seen in the category
“Planning adherence”, showing a decrease from 76%
(2004) to 67% (2009). As mentioned previously, pharma-
ceutical companies did align the processes with suppliers
but struggle with the deployment in daily operations. For
instance, they know the root causes of variance in their
production schedule and are trying to eliminate them.
However, most companies do not share data continuously
internally as well as with customers and suppliers based on
a “rolling production plan” to increase planning adherence.
Effective Management System
The performance indicators for EMS are pointing to the
motivation and empowerment of employees working at the
production site. Figure 6 shows that four elements and their
corresponding management practices and instruments are
considered: “Direction setting”, “Management commitment
and company culture”, “Employee involvement and con-
tinuous improvement”, and “Functional integration and
qualification”.
While the total time of employees absent (e.g., sick
leave) as a percentage of the total working time stayed
constant for 2004 and 2009, fluctuation (employee turnover
on site level) increased from 5.0% to 6.0%. The increase in
fluctuation leads to a loss of knowledge at the production
sites. This “brain-drain” hinders the site organization to
build on existing experiences by staff and management.
Regarding the qualification among staff, a decrease (12% to
10%) of the portion of “unskilled employees” as a
percentage of the total employee on site level could be
observed. However, companies reduced the number of
training days (all kinds of training off and on the job) that
were offered to its employees from 4.0 days in 2004 to
3.0 days in 2009.
In 2009, the overall objectives of the manufacturing
units are closely linked to team or personal objectives of
their shop-floor teams and employees. One explanation can
be the clear breakdown of goals in the corporate strategy
into team and personal objectives in the years between
2004 and 2009. Although the degree of satisfaction
regarding communication of vision, mission, and strategy
decreased, the industry was able to achieve a result in the
80% range. Companies achieved a median score of 83% in
2009 compared with 78% in 2004 for the element
“Direction setting”.
The implementation of practices in the category
“Management Commitment and Company Culture” stayed
stable from 2004 to 2009 with a score of 73%. Companies still
state an intensive involvement of plant management directly
in improvement projects and indirectly by empowering
Implementation levelsKey performance indicators
2009 93 min
79 min2004
+18%
Set-up time
2004
52009
4
+25%Raw material turns
2004
122009
9 +33%
Finished goods turns
2004
22.7 days2009
22.0 days +3%
Cycle time
2004
95 %2009
95 % 0%
Service level
Set-up time reduction
Pull production
Layout optimization
Planning adherence
2009 60 %
2004 52 %
+15%
2009 59 %
2004 44 %
+34%
57 %
2004
2009
68 %
-16%
2009
76 %2004
67 %
-12%
Mean Standard Deviation
77.3 m 31.1 m
80.3 m 31.7 m
Mean Standard Deviation
6.7 9.7
13.7 29.7
Mean Standard Deviation
16%
62% 15%
Mean Standard Deviation
13%
58% 13%
Mean Standard Deviation
16%
61% 16%
Mean Standard Deviation
12.3 11.1
21.1 30.8
Mean Standard Deviation
15%
69% 12%
Mean Standard Deviation
23.2 d 11.7 d
24.4 d 13.4 d
Mean Standard Deviation
88% 20%
89% 12%
56%
50%
67%
73%
Fig. 5 Just-in-time: key performance indicators and implementation levels
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employees for it. The missing improvement concerning this
element is mainly caused by a downward movement in
communication from corporate to site level and information
flow between departments and sites.
Starting at a very low level of 55% in 2004 for the
element “Employee Involvement and Continuous Improve-
ment”, companies were able to increase the value to 69% in
2009. In particular, support from plant management to
corporate level enables staff to continuously solve prob-
lems. Leveraging full potential of practices can be started
with “transferring” authority from supervisors to line staff.
Objective is to give employees the authority to solve
problems on their own when they occur.
The element “Functional Integration and Qualification”
experienced a slight decrease from 70% in 2004 to 68% in
2009. In general, the degree of cross-trained employees
increased in the last years. However, feedback on existing
trainings and job rotation is often not used to systematically
adjust the qualification programs leading to this decrease.
Conclusions
The following conclusions can be drawn from the study:
– As expected, due to the amount of personnel and
financial resources put into efficiency increase in
operations, the industry did make continuous steps
throughout the systems TPM, TQM, JIT, and the
underlying EMS towards the desired state of “Opera-
tional Excellence”, though there are no grand-scale
developments. It can be said that most of the
companies are still working on the effectiveness side
(TPM and TQM) rather than focusing on the efficiency
side (JIT). Taking the model presented in Fig. 2,
pharmaceutical companies are trying to build stable
running machines and stable processes before targeting
the objective of low inventory. It can be argued that the
industry average is not that advanced to already set a
new focus on efficiency. Pharmaceutical companies
took control over their former low asset utilization,
managed to improve the efficiency of their quality
systems, but are still far away from having any kind of
“continuous flow”, smooth production scheduling, or
make-to-order manufacturing.
– For TPM, one could argue that the industry is in a state
of stagnation concerning Total Productive Mainte-
nance. The slight increase in implementing “Preventive
maintenance” linked with a significant increase of
Unplanned Maintenance (performance), leads to the
difficulties in deploying the TPM strategy in the
industry. For instance, a closer look at the element
“Preventive Maintenance” showed that companies are
setting the focus on technical aspects (e.g., checklists
and documentation) rather than the empowerment of
shop-floor employees (machine operators). The objec-
tive of enabling the employees to solve problems
occurred at their machines by themselves as well as
understanding and working on the root causes of
failures is yet to be achieved by the pharmaceutical
industry.
– For TQM, companies were able to increase their
implementation levels regarding Total Quality Man-
agement significantly. The internal “process thinking”
and the management of the downstream interface to
customers were especially improved. The end-to-end
consideration of the value-chain (suppliers–manufac-
turer–customers) supports the steps to a higher quality
Implementation levelsKey performance indicators
2009 6.0 %
2004 5.0 %
+20%
Fluctuation
4.0 %
2004
2009
4.0 % 0%
Absenteeism
3.0 days
2004
2009
4.0 days -25%
Training days
10 %
2004
2009
12 %
-17%
Unskilled employees
2009 83 %
2004 78 % +6%
Direction setting
2009 73 %
2004 73 % 0%
Management Commitment and 
Company Culture
2009 69 %
2004 55 % +25%
Employee Involvement and Continuous 
Improvement
2009 68 %
2004 70 % -3%
Functional Integration and Qualif ication
Mean Standard Deviation
6.8% 5.1%
8.3% 7.6%
Mean Standard Deviation
4.7% 2.2%
4.4% 2.3%
Mean Standard Deviation
13%
82% 14%
Mean Standard Deviation
11%
75% 9%
Mean Standard Deviation
15%
70% 10%
Mean Standard Deviation
6.5 d 10.5 d
4.8 d 4.3 d
Mean Standard Deviation
17%
65% 15%
Mean Standard Deviation
15% 17%
17% 23%
77%
71%
55%
66%
Fig. 6 Effective management system: key performance indicators and implementation levels
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level. It can be argued that the industry is moving from a
cGMP-focused quality system towards a quality culture.
– For JIT, improvements in the indicators for working
capital (e.g., finished goods turns) are mainly a result of
intensified “Pull Production”. Unfortunately, the sec-
ond core measure in JIT “times” increased as well. A
threatening trend is the increase of times for set up and
cleaning as well as for the production cycle from
weighing to packaging. Setbacks in layout optimization
and planning adherence could not be compensated by
improved implementation of pull-system practices and
caused the turn for the worse regarding the results of
some performance indicators.
– For EMS, the decrease of training days from 2004 to
2009 shows that most pharmaceutical sites made one
step backwards regarding the ultimate objective of
“lean” to create a learning organization. This observa-
tion is emphasized by the increase in fluctuation which
leads to a loss of knowledge. The results for the
performance indicators are confirmed by the analysis of
the implementation. Besides “Employee involvement
and continuous improvement”, which improved, all
other categories in this system changed for the worse or
stayed the same. Pharmaceutical companies were not
able to re-design their existing management systems to
facilitate the implementation of a learning organization
with the objective to leverage the potential of high
educational levels among employees.
Appendix A
Appendix B
Appendix C
Table 1 Measurement of TPM implementation
Preventive
maintenance
We have a formal program for maintaining our
machines and equipment.
Maintenance plans and checklists are posted
closely to our machines, and maintenance jobs
are documented.
We emphasize good maintenance as a strategy
for increasing quality and planning for
compliance.
All potential bottleneck machines are identified
and supplied with additional spare parts.
We continuously optimize our maintenance
program based on a dedicated failure analysis.
Our maintenance department focuses on
assisting machine operators perform their own
preventive maintenance.
Our machine operators are actively involved
into the decision-making process when we
decide to buy new machines.
Our machines are mainly maintained internally.
We try to avoid external maintenance service
as far as possible.
Housekeeping Our employees strive to keep our plant neat and
clean.
Our plant procedures emphasize putting all
tools and fixtures in their place.
We have a housekeeping checklist to
continuously monitor the condition and
cleanness of our machines and equipment.
Effective
technology
usage
Our plant is situated at the leading edge of new
technology in our industry.
We are constantly screening the market for new
production technology and assess new
technology concerning its technical and
financial benefit.
We are using new technology very effectively.
We rely on vendors for all of our equipment.
Part of our equipment is protected by the firm’s
patents.
Proprietary process technology and equipment
helps us gain a competitive advantage.
Table 2 Measurement of TPM performance
Key performance
indicator
Definition
Overall equipment
effectiveness (OEE)
OEE=(OEE) Availability×(OEE)
Performance×(OEE) Quality
(OEE) Availability=(Scheduled Time–
Downtime)/Scheduled Time
(OEE) Performance=(Amount Produced×
Ideal Cycle Time)/Available time
(OEE) Quality=(Input-Defects)/Input
Unplanned maintenance Proportion of unplanned maintenance
work as a percentage of the overall time
spent for maintenance (in percent).
Table 3 Measurement of TQM implementation
Process management In our company direct and indirect
processes are well documented.
We continuously measure the quality of
our processes by using process measures
(e.g., On-time-in-full delivery rate).
Our process measures are directly linked to
our plant objectives.
In our company, there are dedicated
process owners who are responsible for
planning, management, and improvement
of their processes.
Table 1 (continued)
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A large percentage of equipment on the
shop floor is currently under statistical
process control.
We make use of statistical process control
to reduce variances in processes.
For root cause analysis, we have
standardized tools to get a deeper
understanding of the influencing factors.
We operate with a high level of process
analytical technology implementation for
real time process monitoring and
controlling.
Cross-functional
product development
Manufacturing engineers are involved to a
great extent in the development of a new
drug formulation and the development of
the necessary production processes.
In our company product and process
development are closely linked to each
other.
Due to close collaboration between the
R&D and the manufacturing department,
we could significantly shorten our time for
product launches (“scale-ups”) in our plant.
For the last couple of years, we have not had
any delays in product launches at our plant.
For product and process transfers between
different units or sites standardized
procedures exist, which ensure a fast,
stable, and complied knowledge transfer.
Customer involvement We are frequently in close contact with our
customers.
Our customers frequently give us feedback
on quality and delivery performance.
We regularly survey our customer’s
requirements.
We regularly conduct customer satisfaction
surveys.
On-time delivery is our philosophy.
We jointly have improvement programs
with our customers to increase our
performance.
Supplier quality
management
Quality is our number one criterion in
selecting suppliers.
We rank our suppliers; therefore, we
conduct supplier qualification and audits.
We use mostly suppliers that we have
validated.
For a large percentage of suppliers, we do
not perform any inspections of the
incoming parts/materials.
Inspections of incoming materials are
usually performed in proportion to the past
quality performance or type of supplier.
Basically, we inspect 100% of our
incoming shipments.
We jointly have improvement programs
with our suppliers to increase our
performance.
Table 3 (continued)
Table 4 Measurement of TQM performance
Key performance
indicator
Definition
Complaint rate
(customer)
Number of complaints as a percentage of all
customer orders delivered (in percent).
Rejected batches Number of rejected batches as a percentage of
all batches produced (in percent).
Complaint rate
(supplier)
Number of complaints as a percentage of all
deliveries received (from your supplier; in
percent).
Table 5 Measurement of JIT implementation
Set-up time
reduction
We are continuously working to lower set-up and
cleaning times in our plant.
We have low set-up times for equipment in our plant.
Our crews practice setups regularly to reduce the
time required.
To increase the flexibility, we put high priority on
reducing batch sizes in our plant.
We have managed to schedule a big portion of our
setups so that the regular up-time of our
machines is usually not affected.
Optimized set-up and cleaning procedures are
documented as best-practice process and rolled-
out throughout the whole plant.
Pull production Our production schedule is designed to allow for
catching up, due to production stoppings because
of problems (e.g., quality problems).
We use a pull system (kanban squares, containers,
or signals) for production control.
We mainly produce according to forecasts.
Suppliers are integrated and vendors fill our
kanban containers, rather than filling our
purchasing orders.
We value long-term associations with suppliers
more than frequent changes in suppliers.
We depend on on-time delivery from our suppliers.
We deliver to our customers in a demand-oriented
JIT way instead of a stock-oriented approach.
We mainly produce one unit when the customer
orders one. We normally do not produce to stock.
Layout
optimization
Our processes are located close together so that
material handling and part storage are minimized.
Products are classified into groups with similar
processing requirements to reduce set-up times.
Products are classified into groups with similar
routing requirements to reduce transportation
time.
The layout of the shop floor facilitates low
inventories and fast throughput.
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As we have classified our products based on their
specific requirements our shop floor layout
can be characterized as separated into
“mini-plants”.
Currently, our manufacturing processes are highly
synchronized over all steps by one takt.
Currently, our manufacturing processes from raw
material to finished goods involve almost no
interruptions and can be described as a full
continuous flow.
At the moment, we are strongly working to reach
the status of a full continuous flow with no
interruption between raw material to finished
goods.
We use “Value Stream Mapping” as a
methodology to visualize and optimize
processes.
Planning
adherence
We usually meet our production plans every day.
We know the root causes of variance in our
production schedule and are continuously trying
to eliminate them.
To increase our planning adherence we share data
with customers and suppliers based on a rolling
production plan.
We have smoothly leveled our production capacity
throughout the whole production process.
Our plant has flexible working shift models so that
we can easily adjust our production capacity
according to current demand changes.
A smoothly leveled production schedule is
preferred to a high level of capacity
utilization.
Table 5 (continued)
Table 6 Measurement of JIT performance
Key performance
indicator
Definition
Set-up time The time for set up and cleaning in percentage
of the scheduled time (in percent).
Raw material
turns
Annual outward raw material movements
divided by average annual raw material
inventory stocks (number).
Finished goods
turns
Annual outward finished goods material
movements divided by average annual
finished goods stocks (number).
Cycle time Time from weighing to packaging (in days).
Service level Perfect order fulfillment (percentage of orders
shipped in time from your site (max.±1 days
of the agreed shipment day) and in the right
quantity (max.±3% of the agreed quantity)
and right quality) to your customer.
Table 7 Measurement of EMS implementation
Direction setting Our production site has an exposed
site vision and strategy that is
closely related to our corporate
mission statement.
Our vision, mission, and strategy is
broadly communicated and lived by
our employees.
Goals and objectives of the
manufacturing unit are closely
linked and consistent with corporate
objectives. The production site has
a clear focus.
The overall objectives of the
production site are closely linked to
the team or personal objectives of
our shop-floor teams and employees.
Our manufacturing managers (head of
manufacturing, site leader, etc.)
have a good understanding of how
the corporate/divisional strategy is
formed.
Our manufacturing managers know
exactly what the most important
criteria for manufacturing jobs are
(i.e., low costs, delivery, quality, etc.).
Management commitment
and company culture
Plant management empowers
employees to continuously improve
the processes and to reduce failure
and scrap rates.
Plant management is personally
involved in improvement projects.
There is too much competition and
too little cooperation between the
departments.
The communication is made via
official channels.
The company has an open
communication culture. There is a
good flow of information between
the departments and the different
management levels.
About innovations we are informed
early enough.
Problems (e.g., reclamations, etc.) are
always traced back to their origin to
identify root causes and to prevent
doing the same mistakes twice.
The achievement of high quality
standards is primarily the task of
our QA/QC departments.
Our employees continuously strive to
reduce any kind of waste in every
process (e.g., waste of time, waste
of production space, etc.).
Command and control is seen as the
most effective leadership style
rather than open culture.
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Employee involvement and
continuous improvement
We have implemented tools and
methods to deploy a continuous
improvement process.
Our employees are involved
in writing policies and
procedures (concerning site
vision down to standard
operating procedures).
Shop-floor employees actively drive
suggestion programs.
Our work teams cannot take
significant actions without
supervisors or middle managers
approval.
Our employees have the authority
to correct problems when they
occur.
Occurring problems should be solved
by supervisors.
Supervisors include their employees
in solving problems.
Our plant forms cross-functional
project teams to solve problems.
The company takes care of the
employees.
We have organized production
employees into teams in
production areas. For each
team there is one dedicated team
member that is responsible for
supervisory tasks.
We have organized production
employees into teams in production
areas. For team leadership we have
an additional supervisory level in
our organization.
Functional integration and
qualification
Each of our employees within our
work teams (in case workers are
organized as teams) is cross-trained
so that they can fill-in for others
when necessary.
At our plant, we have implemented a
formal program to increase the
flexibility of our production
workers. Employees rotate to
maintain their qualification.
In our company there are monthly
open feedback meetings.
The information of these official
feedback meetings is used
systematically in further training.
We continuously invest in
training and qualification of
our workers. We have a
dedicated development
and qualification program
for our production
workers.
Table 7 (continued)
Table 8 Measurement of EMS performance
Key performance
indicator
Definition
Fluctuation Employee turnover at your site (includes all
kinds of fluctuations of employees:
terminations, expired work contracts,
retirements, etc.; in percent).
Absenteeism Total time of employees absent (e.g., sick leave)
as a percentage of the total working time (in
percent).
Training days Number of training days per employee (all
kinds of training off- and on the job; in days
of the year).
Unskilled
employees
Number of unskilled employees as a percentage
of the total number of employees at your site
(in percent).
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